Advances in Hematology / 2012 / Article / Tab 1

Review Article

Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia

Table 1

Selected clinical trials using lenalidomide alone for treatment of CLL. NR: not reported.

StudyRegimenNo. of patientsTLS all gradesTFR all gradesHematologic side effects grade 3/4OR (%)CR (%)OS (%)PFS (%)

Chanan-Khanet al. [14] Phase II
relapsed/refractory CLL
5 mg/d escalated to 25 mg/d455%58%Neutropenia 70% thrombocytopenia 45% anemia 18%479NRNR

Ferrajoli et al. [6]
Phase II relapsed/refractory CLL
10 mg/d escalated to 25 mg/d 44012%Neutropenia 41% thrombocytopenia 15% anemia 3%32773 (with a median follow-up time of 14 months)NR

Chen et al. [16]
Phase II untreated CLL
2.5 mg/descalated to 10 mg/d25088%Neutropenia 72% thrombocytopenia 28% anemia 20%56092 (estimated 2 years OS)89 (estimated 2 years PFS)

Aue et al. [17] Phase II
relapsed/refractory CLL
20 mg/d lowered to 10 mg/d33053%Neutropenia 56% thrombocytopenia 30% anemia 15%NRNRNRNR

Badoux et al. [18]
phase II (elderly) untreated CLL
5 mg/d escalated to 25 mg/d60052%Neutropenia 34% thrombocytopenia 12% anemia <1%651088 (estimated 2 years OS)60 (estimated 2 years PFS)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.